Department of Emergency Medicine, Kirtipur Hospital, Kirtipur, Kathmandu, Nepal.
Department of Intensive Care Unit, Nepal Mediciti Hospital, Bhaisepati, Lalitpur, Nepal.
JNMA J Nepal Med Assoc. 2022 Jul 1;60(251):625-630. doi: 10.31729/jnma.7394.
INTRODUCTION: Antimicrobial resistance is a global health problem. The widespread and improper antibiotics use is the leading cause of antimicrobial resistance. Bacterial co-infection in COVID-19 patients is the basis for the use of antibiotics in the management of COVID-19. COVID-19 pandemic has seriously impacted antibiotic stewardship and increased the global usage of antibiotics, worsening the antimicrobial resistance problem. The use of antibiotics among COVID-19 patients is high but there are limited studies in the context of Nepal. This study aimed to find out the prevalence of antibiotic use among hospitalised COVID-19 patients in a tertiary care centre. METHODS: A descriptive cross-sectional study was conducted on hospitalised COVID-19 patients from April 2021 to June 2021 in a tertiary care centre. Ethical approval was taken from the Institutional Review Committee (Reference number: 2078/79/05). The hospital data were collected in the proforma by reviewing the patient's medical records during the study period of 2 months. Convenience sampling was used. Point estimate and 95% Confidence Interval were calculated. RESULTS: Among 106 hospitalised COVID-19 patients, the prevalence of antibiotic use was 104 (98.11%) (95.52-100, 95% Confidence Interval). About 74 (71.15%) of patients received multiple antibiotics. The most common classes of antibiotics used were cephalosporins, seen in 85 (81.73%) and macrolides, seen in 57 (54.81%) patients. CONCLUSIONS: The prevalence of antibiotic use among hospitalised COVID-19 patients was found to be higher when compared to other studies conducted in similar settings. KEYWORDS: antibiotics; bacterial infection; co-infection; COVID-19.
简介:抗生素耐药性是一个全球性的健康问题。抗生素的广泛和不当使用是导致抗生素耐药性的主要原因。COVID-19 患者的细菌合并感染是 COVID-19 管理中使用抗生素的基础。COVID-19 大流行严重影响了抗生素管理,并增加了全球抗生素的使用,使抗生素耐药性问题更加恶化。COVID-19 患者使用抗生素的情况很高,但在尼泊尔的相关研究有限。本研究旨在了解三级保健中心住院 COVID-19 患者使用抗生素的情况。
方法:在三级保健中心对 2021 年 4 月至 2021 年 6 月住院的 COVID-19 患者进行了一项描述性横断面研究。本研究获得了机构审查委员会的伦理批准(编号:2078/79/05)。在为期 2 个月的研究期间,通过查阅患者病历收集医院数据。使用便利抽样。计算了点估计值和 95%置信区间。
结果:在 106 例住院 COVID-19 患者中,抗生素使用率为 104 例(98.11%)(95.52-100,95%置信区间)。约 74 例(71.15%)患者接受了多种抗生素治疗。使用最多的抗生素类别是头孢菌素,有 85 例(81.73%),大环内酯类有 57 例(54.81%)。
结论:与在类似环境中进行的其他研究相比,住院 COVID-19 患者使用抗生素的比例较高。
关键词:抗生素;细菌感染;合并感染;COVID-19。
JNMA J Nepal Med Assoc. 2022-7-1
JNMA J Nepal Med Assoc. 2023-1-1
JNMA J Nepal Med Assoc. 2022-7-1
JNMA J Nepal Med Assoc. 2023-5-1
JNMA J Nepal Med Assoc. 2023-1-1
JNMA J Nepal Med Assoc. 2023-4-1
PLOS Glob Public Health. 2023-11-14
Clin Infect Dis. 2023-10-16
J Health Popul Nutr. 2023-5-12
Antibiotics (Basel). 2021-12-29
Sci Total Environ. 2022-2-10
Ann Clin Microbiol Antimicrob. 2021-5-21
J Infect Dev Ctries. 2021-4-30
Antibiotics (Basel). 2021-1-29
Indian J Med Res. 2020-5